What Is Lanreotide? Definition and What Research Reports

Definition

Lanreotide is a synthetic cyclic octapeptide that acts as an analogue of the natural hormone somatostatin. It was designed to bind somatostatin receptors — most strongly the subtypes associated with inhibition of growth hormone and of several gut hormones — while resisting the rapid breakdown that limits the native hormone. In the clinical literature the peptide is usually described in its prolonged-release depot form (often written as lanreotide autogel or lanreotide depot), a formulation given by deep subcutaneous injection at long intervals rather than daily. As a term, "lanreotide" is therefore used in two overlapping senses: the peptide molecule itself, and the depot pharmaceutical products built around it.

What Class of Molecule Is It?

Lanreotide belongs to the somatostatin analogue (SSA) class, alongside octreotide and pasireotide. It is a short, chemically synthesised peptide rather than a protein produced by fermentation or a small-molecule drug. Structural work has clarified both how it self-assembles and how it engages its receptor. Using cryo-electron microscopy, researchers determined the atomic structure of lanreotide nanotubes, describing how the peptide organises into ordered tubular assemblies that underlie its self-delivering gel formulation (PMID 35042822). A later structural study examined the binding modes of lanreotide and pasireotide at somatostatin receptor 1, reporting details of how each analogue occupies the receptor pocket (PMID 40487642).

Where the Term Appears in Research

Searches of the biomedical literature place lanreotide overwhelmingly in three research areas: gastroenteropancreatic neuroendocrine tumours (GEP-NETs), acromegaly, and hormone-mediated syndromes such as carcinoid syndrome. It also appears in smaller literatures on rare endocrine conditions and in preclinical work on tumour biology. Lanreotide-containing depot products are approved medicines in multiple jurisdictions for some of these indications; regulatory status differs by country and by formulation, and research-grade peptide material sold for laboratory work is a separate category from approved injectable products.

What the Published Literature Reports

Neuroendocrine tumours

The most cited trial is CLARINET. In that randomised, placebo-controlled study of patients with metastatic enteropancreatic neuroendocrine tumours, lanreotide 120 mg given once every 28 days was associated with significantly prolonged progression-free survival compared with placebo, with median progression-free survival not reached in the lanreotide group versus 18.0 months with placebo (PMID 25014687). Final results of the open-label extension of that programme reported long-term outcomes in patients who continued lanreotide autogel/depot, with the authors describing sustained antiproliferative activity over extended follow-up (PMID 33052555).

Beyond the randomised setting, a real-world analysis examined how lanreotide was used in neuroendocrine tumour practice, reporting on treatment patterns and outcomes outside trial conditions (PMID 37435213). A separate study described patients with gastroenteropancreatic neuroendocrine tumours who were treated with lanreotide depot after prior octreotide long-acting release, reporting on the experience of that sequence (PMID 30788459). Combination approaches have also been tested: the Phase Ib/II PLANET study evaluated pembrolizumab with lanreotide depot in advanced, progressive gastroenteropancreatic neuroendocrine tumours (PMID 39933708).

Carcinoid syndrome

In the ELECT phase 3 programme, investigators prospectively analysed patient-reported symptoms in people with carcinoid syndrome, comparing those who had responded to prior octreotide therapy with those naïve to somatostatin analogue therapy, and reported symptom outcomes for both groups during lanreotide treatment (PMID 29547049).

Acromegaly

Acromegaly is the second large clinical literature. One study of lanreotide 120 mg used as primary therapy assessed tumour shrinkage and ophthalmologic symptoms in acromegaly and reported measurable changes as early as one month after the start of treatment (PMID 35470446). A review of the pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly summarised pharmacokinetic and tolerability data for that formulation (PMID 34664531).

Other settings and preclinical work

A clinical report described the use of lanreotide in congenital hyperinsulinism, a rare disorder of insulin secretion, summarising how the depot analogue was applied in that population (PMID 35587448). On the laboratory side, one study reported that lanreotide induced cytokine modulation in intestinal neuroendocrine tumour models and could overcome resistance to everolimus in that experimental system (PMID 32766136).

How the Literature Is Organised

Tolerability and Adverse Events: What Studies Report

In the randomised CLARINET trial, the most commonly reported treatment-related adverse event was diarrhoea, which occurred more often in the lanreotide group than in the placebo group (PMID 25014687). The open-label extension of that programme reported that no new safety signals emerged with prolonged exposure to lanreotide autogel/depot (PMID 33052555). A dedicated review of the prolonged-release formulation in acromegaly likewise summarised the safety profile reported across the acromegaly literature, including gastrointestinal and hepatobiliary events characteristic of the somatostatin analogue class (PMID 34664531). Adverse-event frequencies differ by indication, formulation and study population, so figures from one trial do not transfer automatically to another.

Limits of the Evidence

• Most of the strongest data come from oncology and endocrinology populations with specific diagnoses, not from healthy volunteers.
• Depot formulations behave differently from plain peptide solutions; structural work has shown that the formulation depends on ordered self-assembly of the peptide itself (PMID 35042822).
• Preclinical findings, such as the cytokine modulation and everolimus-resistance results in intestinal neuroendocrine tumour models (PMID 32766136), describe laboratory systems and were not clinical outcomes.
• Combination strategies remain early-phase; the PLANET study was a Phase Ib/II evaluation rather than a definitive trial (PMID 39933708).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision. Nothing here describes a protocol, and no information on this page should be read as a suggestion to use lanreotide or any other compound.

References

• Lanreotide in metastatic enteropancreatic neuroendocrine tumors (The New England Journal of Medicine, 2014)
• Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study (Endocrine, 2021)
• Real world use of lanreotide in neuroendocrine tumors (Journal of Gastrointestinal Oncology, 2023)
• Atomic structure of Lanreotide nanotubes revealed by cryo-EM (PNAS, 2022)
• Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus (Frontiers in Oncology, 2020)
• Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors (Journal of Pancreatic Cancer, 2018)
• The Use of Lanreotide in the Treatment of Congenital Hyperinsulinism (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Efficacy of lanreotide 120 mg primary therapy on tumour shrinkage and ophthalmologic symptoms in acromegaly after 1 month (Clinical Endocrinology, 2022)
• Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly (Expert Review of Clinical Pharmacology, 2021)
• Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET) (Journal of Neuroendocrinology, 2025)
• Structural insights into the binding modes of lanreotide and pasireotide with somatostatin receptor 1 (Acta Pharmaceutica Sinica B, 2025)
• Lanreotide therapy in carcinoid syndrome: prospective analysis of patient-reported symptoms in the ELECT phase 3 study (Endocrine Practice, 2018)